A double-blinded, randomized, controlled phase 2A safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild
Ended Project Grant Awarded Last action
- Award ID
- R01AG051596
- Recipient
-
Pharmatrophix Inc. UEI LBF9YJ9QGLJ5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,299,042
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Funding
-
- $7,299,044.28 Federal
- -$1.86 Non-federal
- Place of performance
- Menlo Park, CA 94025, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$2 | $0 | |
| Amendment | -$2 | -$2 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $2,559,183 | $0 | |
| Amendment | $245,000 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,495,447 | $0 | |
| Amendment | $1,499,544 | $0 | |
| Original award | $1,499,874 | $0 |
Show all 15
Quick answers
Who received award R01AG051596?
R01AG051596 was awarded to Pharmatrophix Inc. by National Institute on Aging (National Institutes of Health) on September 15, 2016.
How much is award R01AG051596 worth?
$7,299,042 has been obligated on R01AG051596: $7,299,044 in federal funding and -$2 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award